Comprehensive Whole‐Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review
Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade-long expertise in managing recurrent cases, we advocate the adoption of Programmed Death-1 (PD-1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious treatment option.
Authors
- Hua Mi (ORCID: https://orcid.org/0000-0002-4432-0386)
- P. Hu (ORCID: https://orcid.org/0009-0000-5026-2293)
- Di Chen (ORCID: https://orcid.org/0000-0002-0758-1763)
- Jun Qing Yu (ORCID: https://orcid.org/0000-0001-5008-2153)
Institutions
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1002/ccr3.70418
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00